All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The 23rd Congress of the European Hematology Association (EHA) took place in Stockholm from 14–17 June 2018 and on Friday 15 June an oral session took place in which Paola Tacchetti from the University of Bologna, Seràgnoli Institute of Hematology, Bologna, Italy, presented the final data from the phase III GIMEMA-MMY-3006 trial. The phase III GIMEMA-MMY-3006 study compared the use of bortezomib (V) on top of a backbone regimen of thalidomide-dexamethasone (TD) with TD alone, before and after double autologous stem-cell transplantation (ASCT), in newly diagnosed multiple myeloma (NDMM) patients. Data from an interim analysis of this study at 36 months was published in The Lancet in 2010, but at the time there was no overall survival (OS) analysis.
Bortezomib-based induction regimens are now widely used as a standard of care (SOC) worldwide, but no trial to date has shown an OS benefit from the inclusion of bortezomib in ASCT protocols. Dr Tacchetti explained that a long-term follow up is necessary in order to determine OS benefits, to explore the possibility of negative effects on therapies further down the line, to assess the emergence of drug-resistant clones, and to evaluate long-term adverse events (AEs) such as secondary primary malignancies (SPMs).
Data is given as VTD vs TD:
This extensive follow-up of 10 years shows that there is a PFS benefit that extends into a longer TTnT, PFS2, as well as an extended OS in both the overall population and high- and standard- risk subgroups. Following first relapse, the outcomes did not differ significantly, and there was a similar incidence of SPMs. Overall the inclusion of bortezomib into a triplet-based regimen that includes an IMiD along with double ASCT, led to an estimated 10-year PFS of 60%. Ongoing clinical trials are now assessing the benefit of quadruplet combinations upfront.
Dr Tacchetti was asked to comment on why the OS curves did not separate between VTD and TD for 4 or 5 years. She explained that it is difficult to explain why but really illustrates the importance of long-term follow-ups. The impressive 10-year PFS of 34% was also commented on and Dr Tacchetti was asked whether they were able to identify the patients that benefit and if after 6 or 7 years they remained in a plateau or relapsed. Dr Tacchetti explained that the majority of patients that had a greater OS had standard cytogenetics and were ISS stage I and that these patients also achieved a complete remission, as well as a complete response. She added that it would be interesting to have data on MRD, but that this is ongoing. Most of these patients have achieved a plateau, but she said that they need to separate out a fraction of patients who have relapsed to see this more clearly.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox